Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Andrea Sartore-Bianchi; Federica Di Nicolantonio; Michele Nichelatti; Francesca Molinari; Sara De Dosso; Piercarlo Saletti; Miriam Martini; Tiziana Cipani; Giovanna Marrapese; Luca Mazzucchelli; Simona Lamba; Silvio Veronese; Milo Frattini; Alberto Bardelli; Salvatore Siena

doi:10.1371/journal.pone.0007287

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Andrea Sartore-Bianchi, Federica Di Nicolantonio, Michele Nichelatti, Francesca Molinari, Sara De Dosso, Piercarlo Saletti, Miriam Martini, Tiziana Cipani, Giovanna Marrapese, Luca Mazzucchelli, Simona Lamba, Silvio Veronese, Milo Frattini, Alberto Bardelli, Salvatore Siena

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Background: KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methodology/Principal Findings: We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p

Original language	English
Article number	e7287
Journal	PLoS One
Volume	4
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0007287
Publication status	Published - Oct 2 2009

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Access to Document

10.1371/journal.pone.0007287

Fingerprint Dive into the research topics of 'Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer'. Together they form a unique fingerprint.

Cite this

Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., Lamba, S., Veronese, S., Frattini, M., Bardelli, A., & Siena, S. (2009). Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One, 4(10), [e7287]. https://doi.org/10.1371/journal.pone.0007287

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. / Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Nichelatti, Michele; Molinari, Francesca; De Dosso, Sara; Saletti, Piercarlo; Martini, Miriam; Cipani, Tiziana; Marrapese, Giovanna; Mazzucchelli, Luca; Lamba, Simona; Veronese, Silvio; Frattini, Milo; Bardelli, Alberto; Siena, Salvatore.

In: PLoS One, Vol. 4, No. 10, e7287, 02.10.2009.

Research output: Contribution to journal › Article › peer-review

Sartore-Bianchi, A, Di Nicolantonio, F, Nichelatti, M, Molinari, F, De Dosso, S, Saletti, P, Martini, M, Cipani, T, Marrapese, G, Mazzucchelli, L, Lamba, S, Veronese, S, Frattini, M, Bardelli, A & Siena, S 2009, 'Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer', PLoS One, vol. 4, no. 10, e7287. https://doi.org/10.1371/journal.pone.0007287

Sartore-Bianchi, Andrea ; Di Nicolantonio, Federica ; Nichelatti, Michele ; Molinari, Francesca ; De Dosso, Sara ; Saletti, Piercarlo ; Martini, Miriam ; Cipani, Tiziana ; Marrapese, Giovanna ; Mazzucchelli, Luca ; Lamba, Simona ; Veronese, Silvio ; Frattini, Milo ; Bardelli, Alberto ; Siena, Salvatore. / Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. In: PLoS One. 2009 ; Vol. 4, No. 10.

@article{72f846b70f5b40698266b5bb4a26bca0,

title = "Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer",

abstract = "Background: KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methodology/Principal Findings: We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p",

author = "Andrea Sartore-Bianchi and {Di Nicolantonio}, Federica and Michele Nichelatti and Francesca Molinari and {De Dosso}, Sara and Piercarlo Saletti and Miriam Martini and Tiziana Cipani and Giovanna Marrapese and Luca Mazzucchelli and Simona Lamba and Silvio Veronese and Milo Frattini and Alberto Bardelli and Salvatore Siena",

year = "2009",

month = oct,

day = "2",

doi = "10.1371/journal.pone.0007287",

language = "English",

volume = "4",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

AU - Sartore-Bianchi, Andrea

AU - Di Nicolantonio, Federica

AU - Nichelatti, Michele

AU - Molinari, Francesca

AU - De Dosso, Sara

AU - Saletti, Piercarlo

AU - Martini, Miriam

AU - Cipani, Tiziana

AU - Marrapese, Giovanna

AU - Mazzucchelli, Luca

AU - Lamba, Simona

AU - Veronese, Silvio

AU - Frattini, Milo

AU - Bardelli, Alberto

AU - Siena, Salvatore

PY - 2009/10/2

Y1 - 2009/10/2

N2 - Background: KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methodology/Principal Findings: We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p

AB - Background: KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methodology/Principal Findings: We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p

UR - http://www.scopus.com/inward/record.url?scp=70350028742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350028742&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0007287

DO - 10.1371/journal.pone.0007287

M3 - Article

C2 - 19806185

AN - SCOPUS:70350028742

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e7287

ER -